Literature DB >> 14529686

[18F]fluorodeoxyglucose positron emission tomography as a useful indicator of metastatic gestational trophoblastic tumor: preliminary results in three patients.

S Sironi1, M Picchio, G Mangili, E Garavaglia, B Zangheri, C Messa, C Voci, G L Taccagni, A del Maschio, F Fazio.   

Abstract

OBJECTIVE: The goal of this study was to evaluate the usefulness of positron emission tomography with [(18)F]fluorodeoxyglucose ([(18)F]FDG-PET) in detecting metastases in patients with gestational trophoblastic tumor (GTTs).
METHODS: A retrospective study was conducted on three patients with GTTs who had been studied with [(18)F]FDG-PET and computed tomography (CT) after an increase in human chorionic beta-gonadotropin (betahCG) serum levels. PET scans were performed with a multiring whole-body positron emission tomograph 45 min after an intravenous bolus injection of [(18)F]FDG ( approximately 5.2 MBq/kg). CT studies were obtained on a spiral scanner prior and after administration of intravenous iodinated contrast material. Within a week of CT and [(18)F]FDG-PET studies, the patients underwent surgical procedures for histological diagnosis.
RESULTS: In one patient, a lung lesion positive for neoplastic tissue with [(18)F]FDG-PET and negative with CT was confirmed to be a GTT metastasis at histology. In another patient, [(18)F]FDG-PET was negative, while CT was positive for the presence of lung metastasis; no viable tumor tissue was found at histological analysis. The remaining patient had a positive [(18)F]FDG-PET and CT study for lung metastasis; this was confirmed at histological analysis. In the same patient, both [(18)F]FDG-PET and CT depicted the presence of a liver lesion. Necrotic lesion regression after treatment was clearly documented with [(18)F]FDG-PET only.
CONCLUSIONS: Our preliminary results suggest that [(18)F]FDG-PET may be useful for the assessment of metastatic disease in patients with GTTs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14529686     DOI: 10.1016/s0090-8258(03)00437-2

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Role of PET-CT Scan in Gynaeconcology.

Authors:  Ashwini A Pawar; Digvijay B Patil; Shilpa Patel; Meeta Mankad; Pariseema Dave
Journal:  J Obstet Gynaecol India       Date:  2015-05-05

2.  The role of 18F-fluorodeoxyglucose positron emission tomography in gestational trophoblastic tumours: a pilot study.

Authors:  Ting Chang Chang; Tzu Chen Yen; Yiu Tai Li; Yen Ching Wu; Yu Cheng Chang; Koon Kwan Ng; Shih Ming Jung; Tzu I Wu; Chyong Huey Lai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-12       Impact factor: 9.236

3.  Role of 18F-FDG PET in the management of gestational trophoblastic neoplasia.

Authors:  P Mapelli; G Mangili; M Picchio; C Gentile; E Rabaiotti; V Giorgione; E G Spinapolice; L Gianolli; C Messa; M Candiani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-12       Impact factor: 9.236

Review 4.  Imaging Features of Uncommon Gynecologic Cancers.

Authors:  Maura Miccò; Evis Sala; Yulia Lakhman; Hedvig Hricak; Hebert Alberto Vargas
Journal:  AJR Am J Roentgenol       Date:  2015-12       Impact factor: 3.959

5.  [Clinical and radiological features of gestational trophoblastic tumors].

Authors:  Nisrine Mamouni; Siham Boumhaoued; Sanae Erraghay; Meriem Boubou; Chahrazed Bouchikhi; Abdelaziz Banani
Journal:  Pan Afr Med J       Date:  2017-11-14

6.  Rare Case of a Young Female With Co-existent Hydatidiform Mole and Pulmonary Metastases: An Underrecognized Entity.

Authors:  Ravikanth Reddy
Journal:  Cureus       Date:  2021-12-07

7.  Case Report: 18F-FDG PET/CT and Laparoscopic Nephron Sparing Surgery in the Management of Bleeding From Renal Metastases of Choriocarcinoma.

Authors:  Yuancheng Du; Xueping Zhang; Shengyang Sun; Meihong Sun; Dongyu Yang; Xinyuan Yu; Kehao Li; Jie Ma; Yongxiang Li; Jinming Ge; Changqing Liu; Liang Qiao
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.